These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25446428)

  • 1. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a.
    Halai R; Bellows-Peterson ML; Branchett W; Smadbeck J; Kieslich CA; Croker DE; Cooper MA; Morikis D; Woodruff TM; Floudas CA; Monk PN
    Eur J Pharmacol; 2014 Dec; 745():176-81. PubMed ID: 25446428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease.
    Li L; Chen L; Zang J; Tang X; Liu Y; Zhang J; Bai L; Yin Q; Lu Y; Cheng J; Fu P; Liu F
    Metabolism; 2015 May; 64(5):597-610. PubMed ID: 25682062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric receptors of the human C3a receptor and C5a receptor (CD88).
    Crass T; Ames RS; Sarau HM; Tornetta MA; Foley JJ; Köhl J; Klos A; Bautsch W
    J Biol Chem; 1999 Mar; 274(13):8367-70. PubMed ID: 10085065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic small-molecule complement inhibitors.
    Holland MC; Morikis D; Lambris JD
    Curr Opin Investig Drugs; 2004 Nov; 5(11):1164-73. PubMed ID: 15573867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
    Pellas TC; Boyar W; van Oostrum J; Wasvary J; Fryer LR; Pastor G; Sills M; Braunwalder A; Yarwood DR; Kramer R; Kimble E; Hadala J; Haston W; Moreira-Ludewig R; Uziel-Fusi S; Peters P; Bill K; Wennogle LP
    J Immunol; 1998 Jun; 160(11):5616-21. PubMed ID: 9605167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74).
    Cain SA; Monk PN
    J Biol Chem; 2002 Mar; 277(9):7165-9. PubMed ID: 11773063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a.
    Gutzmer R; Köther B; Zwirner J; Dijkstra D; Purwar R; Wittmann M; Werfel T
    J Invest Dermatol; 2006 Nov; 126(11):2422-9. PubMed ID: 16778800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization.
    Bock D; Martin U; Gärtner S; Rheinheimer C; Raffetseder U; Arseniev L; Barker MD; Monk PN; Bautsch W; Köhl J; Klos A
    Eur J Immunol; 1997 Jun; 27(6):1522-9. PubMed ID: 9209506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells.
    Takabayashi T; Shimizu S; Clark BD; Beinborn M; Burke JF; Gelfand JA
    Surgery; 2004 May; 135(5):544-54. PubMed ID: 15118592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
    March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
    Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement factors C3a and C5a have distinct hemodynamic effects in the rat.
    Proctor LM; Moore TA; Monk PN; Sanderson SD; Taylor SM; Woodruff TM
    Int Immunopharmacol; 2009 Jun; 9(6):800-6. PubMed ID: 19285573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists.
    Li XX; Clark RJ; Woodruff TM
    Int Immunopharmacol; 2021 Nov; 100():108074. PubMed ID: 34454293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
    Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
    Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models.
    Ames RS; Lee D; Foley JJ; Jurewicz AJ; Tornetta MA; Bautsch W; Settmacher B; Klos A; Erhard KF; Cousins RD; Sulpizio AC; Hieble JP; McCafferty G; Ward KW; Adams JL; Bondinell WE; Underwood DC; Osborn RR; Badger AM; Sarau HM
    J Immunol; 2001 May; 166(10):6341-8. PubMed ID: 11342658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy.
    Liu L; Zhang Y; Duan X; Peng Q; Liu Q; Zhou Y; Quan S; Xing G
    J Clin Immunol; 2014 Feb; 34(2):224-32. PubMed ID: 24327134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling.
    Lim J; Iyer A; Suen JY; Seow V; Reid RC; Brown L; Fairlie DP
    FASEB J; 2013 Feb; 27(2):822-31. PubMed ID: 23118029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
    Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
    J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Complement C3a and C5a Signaling in Renal Diseases: A Bridge between Acute and Chronic Inflammation.
    Buelli S; Imberti B; Morigi M
    Nephron; 2024; 148(10):712-723. PubMed ID: 38452744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.
    Bubeck P; Grötzinger J; Winkler M; Köhl J; Wollmer A; Klos A; Bautsch W
    Eur J Biochem; 1994 Feb; 219(3):897-904. PubMed ID: 8112341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.
    Proctor LM; Arumugam TV; Shiels I; Reid RC; Fairlie DP; Taylor SM
    Br J Pharmacol; 2004 Jun; 142(4):756-64. PubMed ID: 15159277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.